Arrowhead Pharmaceuticals Corp (ARWR) Tops Q2 EPS by 5c
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $81.57 -0.52%
Revenue Growth %: +89.5%
Financial Fact:
TOTAL OTHER INCOME (EXPENSE): -79.26K
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +89.5%
Financial Fact:
TOTAL OTHER INCOME (EXPENSE): -79.26K
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Corp (NASDAQ: ARWR) reported Q2 EPS of $0.24, $0.05 better than the analyst estimate of $0.19. Revenue for the quarter came in at $48.15 million versus the consensus estimate of $42.99 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Corp (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
- Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
- AMC Entertainment prices $200M stock offering to redeem senior notes
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
